Jump to Main Content
- Riederer, A., et al. Show all 7 Authors
- The veterinary journal 2017 v.219 pp. 60-64
- blood glucose; cats; drugs; glucose; hypoglycemia; insulin; neck; tissues
- ... The aim of this study was to examine the safety and reliability of a research-grade implantable pump for controlled delivery of insulin glargine in cats. For this purpose, a small telemetrically controlled drug delivery pump with a refillable reservoir was implanted into the subcutaneous tissues of the dorsal neck in 10 clinically healthy cats. The reservoir was filled with insulin glargine, and t ...
- Riederer, A., et al. Show all 8 Authors
- The veterinary journal 2017 v.225 pp. 50-55
- cats; diabetes mellitus; echocardiography; heart failure; humans; laboratory animals; people; prospective studies; remission; risk; therapeutics
- ... Diabetes mellitus (DM) can result in cardiovascular dysfunction and heart failure characterized by diastolic dysfunction with or without the presence of systolic dysfunction in people and laboratory animals. The objective of this prospective study was to determine if cats with newly diagnosed DM had myocardial dysfunction and, if present, whether it would progress if appropriate antidiabetic thera ...
- Riederer, A., et al. Show all 9 Authors
- Journal of veterinary internal medicine 2016 v.30 no.1 pp. 92-100
- appetite; body weight; cats; clinical trials; glucagon; glucagon-like peptide 1; humans; insulin; insulin secretion; low carbohydrate diet; noninsulin-dependent diabetes mellitus; placebos; remission; satiety; statistical analysis; vomiting; weight gain
- ... BACKGROUND: Exenatide extended release (ER) is a glucagon‐like peptide‐1 analogue that increases insulin secretion, inhibits glucagon secretion and induces satiation in humans with type 2 diabetes mellitus. The use of exenatide ER is safe and stimulates insulin secretion in healthy cats. OBJECTIVES: The objective of this study is to assess the safety of exenatide ER and its effect on body weight, ...
- PubMed Central: